Hong Ruoxi, Dai Zhen, Zhu Wenjie, Xu Binghe
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chengdu Center for Disease Control and Prevention, Chengdu, China.
PLoS One. 2015 Oct 29;10(10):e0138908. doi: 10.1371/journal.pone.0138908. eCollection 2015.
Results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial indicated that complete axillary node dissection (ALND) may not be warranted in some breast cancer patients with low tumor burden who are undergoing breast-conserving surgery following whole-breast irradiation. However, this study did not address patients undergoing mastectomy or those undergoing breast-conserving surgery without whole-breast radiotherapy. Given that lymph node ratio (LNR; ratio of positive lymph nodes to the total number removed) has been shown to be a prognostic factor in breast cancer, we first sought to determine the prognostic value of LNR in a low risk population comparable to that of the Z0011 trial and further to investigate whether the prognostic significance differs with local treatment modality.
We used the Surveillance Epidemiology and End Results (SEER) database to identify breast cancer patients with T1-T2 tumor and 1-2 positive nodes. Patients were subclassified by the local therapy they underwent for the primary tumor. The prognostic value of LNR in predicting disease-specific survival (DSS) was examined in each treatment group.
A total of 53,109 patients were included. In the subgroup of 20,602 patients who underwent lumpectomy following radiotherapy, LNR was not found to be significantly associated with DSS in both the univariate and multivariate model. For the 4,664 patients treated with mastectomy following radiotherapy, 6,811 treated with lumpectomy without radiotherapy and 21,031 with mastectomy without radiotherapy, LNR independently predict DSS in each of these subgroups.
Our results add evidence to the concept that axillary dissection could be omitted in patients with one or two positive nodes following breast-conserving surgery and whole breast radiation.
美国外科医师学会肿瘤学组(ACOSOG)Z0011试验结果表明,对于一些肿瘤负荷较低、接受全乳照射后行保乳手术的乳腺癌患者,可能无需进行腋窝淋巴结清扫术(ALND)。然而,该研究未涉及接受乳房切除术的患者或未接受全乳放疗而行保乳手术的患者。鉴于淋巴结比率(LNR;阳性淋巴结数与切除的淋巴结总数之比)已被证明是乳腺癌的一个预后因素,我们首先试图确定LNR在与Z0011试验类似的低风险人群中的预后价值,并进一步研究其预后意义是否因局部治疗方式而异。
我们使用监测、流行病学和最终结果(SEER)数据库来识别患有T1 - T2期肿瘤且有1 - 2个阳性淋巴结的乳腺癌患者。患者根据其对原发肿瘤所接受的局部治疗进行亚分类。在每个治疗组中检查LNR预测疾病特异性生存(DSS)的预后价值。
共纳入53,109例患者。在放疗后接受保乳手术的20,602例患者亚组中,单因素和多因素模型均未发现LNR与DSS有显著相关性。对于放疗后接受乳房切除术的4,664例患者、未接受放疗而行保乳手术的6,811例患者以及未接受放疗而行乳房切除术的21,031例患者,LNR在这些亚组中均独立预测DSS。
我们的结果为以下概念增加了证据,即对于保乳手术和全乳放疗后有1或2个阳性淋巴结的患者,可以省略腋窝清扫术。